Report error Found 354 Enz. Inhib. hit(s) with all data for entry = 10914
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.80nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 2.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 3.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 3.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair